Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad,
CA 92008-7208
United States - Map
Phone: 760-931-9200
Fax: 760-603-2700
Web Site: http://www.isispharm.com
| Isis Pharmaceuticals, Inc., through its drug discovery platform based on antisense technology, discovers and develops drugs that bind to RNA antisense technology. The company has commercialized its antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. It licenses its drugs to partners prior to late-phase development and commercialization. The company and Alnylam Pharmaceuticals jointly own Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA therapeutics. Isis is the owner or exclusive licensee of approximately 1,600 issued patents worldwide. The company was founded in 1989 and is based in Carlsbad, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Stanley T. Crooke M.D., Ph.D., 63
Founder, Chairman, Chief Exec. Officer and Pres |
$
1.09M |
$
79.00K | Ms. B. Lynne Parshall J.D., 54
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Sec. |
$
863.00K |
$
15.00K | Dr. Kleanthis G. Xanthopoulos Ph.D., 50
Sr. VP, Chief Exec. Officer of Regulus Therapeutics Inc and Pres of Regulus Therapeutics Inc |
$
623.00K | N/A | Dr. C. Frank Bennett Ph.D., 52
Sr. VP of Research |
$
516.00K |
$
351.00K | Dr. Richard S. Geary Ph.D, 51
Sr. VP of Devel. |
$
450.00K |
$
34.00K |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
